Wockhardt Limited

NSEI:WOCKPHARMA 주식 보고서

시가총액: ₹190.9b

Wockhardt 미래 성장

Future 기준 확인 0/6

현재 Wockhardt 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장17.7%
매출 성장률n/a
향후 자기자본 수익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 02
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Aug 20
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jul 27
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 30
Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Jun 22
Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Feb 21
Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

Dec 19
There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Oct 14
There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Jun 23
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Feb 18
Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jan 04
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Jul 26
Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

May 18
Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Jan 26
Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Dec 01
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Wockhardt 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NSEI:WOCKPHARMA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
9/30/202429,810-2,880-1,7801,470N/A
6/30/202429,250-3,430N/AN/AN/A
3/31/202428,300-4,630302,190N/A
12/31/202327,760-5,010N/AN/AN/A
9/30/202327,740-5,140201,960N/A
6/30/202327,000-6,260N/AN/AN/A
3/31/202326,570-5,590-5601,530N/A
12/31/202226,280-6,100N/AN/AN/A
9/30/202227,820-5,2102402,250N/A
6/30/202229,650-2,980N/AN/AN/A
3/31/202232,300-2,4402,0104,130N/A
12/31/202132,074-787N/AN/AN/A
9/30/202131,175-5671,7142,857N/A
6/30/202129,696-867N/AN/AN/A
3/31/202127,080-2,990-3,570-2,870N/A
12/31/202027,633-1,780N/AN/AN/A
9/30/202024,910-2,583-2,486-896N/A
6/30/202027,167-3,181N/AN/AN/A
3/31/202028,440-1,6384,7666,490N/A
12/31/201935,136-1,320N/AN/AN/A
9/30/201936,903-2,1274,7857,311N/A
6/30/201940,138-1,533N/AN/AN/A
3/31/201935,658-2,897-9151,833N/A
12/31/201841,851-3,346N/AN/AN/A
9/30/201841,445-3,043N/AN/AN/A
6/30/201840,536-2,848N/AN/AN/A
3/31/201839,245-6,083N/A684N/A
12/31/201737,822-6,285N/AN/AN/A
9/30/201737,724-6,416N/AN/AN/A
6/30/201738,148-6,213N/AN/AN/A
3/31/201739,664-1,957N/A-2,695N/A
12/31/201641,695485N/AN/AN/A
9/30/201642,4851,745N/AN/AN/A
6/30/201644,1342,499N/AN/AN/A
3/31/201644,5322,507N/A716N/A
12/31/201546,0853,168N/AN/AN/A
9/30/201549,1486,031N/AN/AN/A
6/30/201545,4974,992N/AN/AN/A
3/31/201544,8154,049N/A3,550N/A
12/31/201443,8674,452N/AN/AN/A
9/30/201442,4104,024N/AN/AN/A
6/30/201444,6325,374N/AN/AN/A
3/31/201448,3048,407N/A14,763N/A
12/31/201352,77211,010N/AN/AN/A

애널리스트 미래 성장 예측

수입 대 저축률: WOCKPHARMA 의 예상 수익 증가율이 절약률( 6.7% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: WOCKPHARMA 의 수익이 Indian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: WOCKPHARMA 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: WOCKPHARMA 의 수익이 Indian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: WOCKPHARMA 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: WOCKPHARMA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y